BI 831266

Drug Profile

BI 831266

Latest Information Update: 23 Apr 2012

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Apr 2012 BI 831266 is still in phase I trials for Solid tumours
  • 19 Aug 2010 Boehringer Ingelheim completes enrolment in its phase I trial [NCT00756223] for Solid tumours in Austria
  • 26 Nov 2008 Phase-I clinical trials in Solid tumours in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top